Futura Medical Plc

Futura Medical Plc
FUM.L
ISIN: GB0033278473
Symbol: GYX


Futuramedical.com


Billiger und schneller als Viagra: Neue Potenzcreme enthält Sprengstoff Nitroglycerin

Wie „The Sun“ berichtet, habe das Gel bei sieben von zehn Männern mit Erektionsstörungen eingeschlagen wie eine Bombe. Schon eine erbsengroße Menge der Creme habe ausgereicht, um ein positives Ergebnis zu erzielen. Das Potenzmittel wirke zudem bis zu zwölf Mal schneller als Viagra. 

Von 0 auf Erektion in weniger als zehn Minuten

Interim Results


Futura Medical kicks off Phase III study on erectile dysfunction gel




Eine interessante Idee und ein wirklicher Hotstock. 

Hab mal ein paar Stück eingesammelt.
Ich meine die Aktie und nicht eines ihrer Produkte! 

Ist noch wer von euch an Board?   Meinungen dazu?

nach deinem beitrag waren wir heftig am diskutieren, natürlich erstmal super produkt...doch kann kamen die ersten zweifel...

oralverkehr ohne gummi, was passiert mit der zunge der frau?

aber ich tippe mal das wird alles in phase 3 getestet...

knappe 40% plau seit vorstellung...

Die läuft und läuft und läuft, ... 

Nächsten Montag wissen wir wahrscheinlich mehr, da ist Research & Development Day:

R&D Day im Februar

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio
of innovative products for sexual health and pain relief, today announces plans to host an R&D Day
in London for analysts and institutional investors on Monday 11 February 2019.


The event will feature a presentation from a Key Opinion Leader in erectile dysfunction ("ED")
and will provide an opportunity to hear about the Company, its R&D strategy with a focus on
its DermaSys® drug delivery technology and lead product MED2005, a topical glyceryl trinitrate 
("GTN") gel for the treatment of ED.

James Barder, Chief Executive Officer of Futura Medical, said:
"We are looking forward to hosting the event which will build on our initial Advisory Panel meeting
hosted by Futura at the 19th Annual Fall Scientific Meeting of Sexual Medicines Society of
North America in November 2018, and was extremely well received and productive. The Advisory Panel
were unanimous in their view that there has been little recent credible innovation in the treatment of ED.
They were therefore excited by the meaningful PK and Phase 2 findings presented on our lead programme MED2005, demonstrating the potential of MED2005 as both a topical and fast-acting erectile dysfunction
treatment, key differentiators to other ED products on the market. There was also a unanimous desire
by the panel to remain involved with the development programme for MED2005 and the panel look
forward to reviewing the results from our ongoing Phase 3 trial when published in Q4 2019."

Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of Andrology at Tulane
University School of Medicine in New Orleans and member of the
Futura Medical Advisory Panel, said:
"The treatment of ED has not seen any new clinical products for nearly two decades.
MED2005 is a novel glyceryl trinitrate (GTN) topical gel with an enhanced absorption delivery system.
After application to the glans penis, there is a rapid onset of action (5-10 mins in 70% of 
spontaneous attempts at intercourse) in contrast to current oral PDE5i's, which can take 30-90 mins
to act. This novel topical therapy is easy to use, does not have any food or alcohol interactions,
and has excellent tolerability for both patient and partner.

"I am excited to be part of an advisory panel helping to shape the future programme for MED2005 
as it enters Phase 3 studies, and I look forward to ultimate approval by the FDA and regulators 
around the world. It offers new hope to patients who, for whatever reason, are dissatisfied with
current therapies or are precluded from their use."
In October 2018, Futura announced that the first patient had been enrolled in the first Phase 3 study,
("FM57") of MED2005 that will recruit approximately 1,000 patients with mild, moderate or severe
ED across nine countries in Central and Eastern Europe. The Phase 3 study remains on track,
with headline data expected by the end of 2019.
For further information on the R&D day, or to register your interest, please contact Optimum
Strategic Communications at futuramedical@optimumcomms.com. Further information will 
be made available in January 2019.
The event will be webcast and will be made available on the investor section of website shortly after the event.

Ich bin am 18ten Jänner eingestiegen. Diese Aktie läuft und läuft und läuft. 

Ist jemand dabei von euch?

https://www.finanzen.net/aktien/Futura_Medical-Aktie

ein kumpel von mir hat sie auf meine idee, die ich von dir hatte gekauft...;-)

Meinst du jetzt die Potenzcreme oder die Aktie? 

die creme gibts ja noch nicht...gibts eigentlich ein zeitfenster für die einzelnen testphasen?

https://futuramedical.com/content/products/med_2005.asp
https://clinicaltrials.gov/ct2/show/stud...=12&rank=5

First patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

Vielleicht beteiligt sich ja schon wer, denn +20% heute sind schon a Wahnsinn! 

Unsere Lieblingsaktie hat heute wieder mal +20% zugelegt, da ist fix was im Busch.
Ich konnte aber leider auch noch keine Details finden.